Related Experiment Videos
Genotyping of thiopurine methyltransferase using pyrosequencing
Yuko Okada1, Katsunori Nakamura, Masanori Wada
1Department of Clinical Pharmacology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Biological & Pharmaceutical Bulletin
|April 2, 2005
Summary
A new Pyrosequencing method accurately determines Thiopurine Methyltransferase (TPMT) genotypes, identifying mutations linked to severe drug toxicity. This rapid TPMT genotyping is crucial for safe thiopurine drug use in patients.
Area of Science:
- Pharmacogenomics
- Molecular Diagnostics
- Genetics
Background:
- Thiopurine drugs (e.g., 6-mercaptopurine, azathioprine) are vital for treating leukemia and autoimmune diseases.
- Genetic variations in the Thiopurine Methyltransferase (TPMT) gene can lead to severe, life-threatening toxicity from these drugs.
- Existing methods for TPMT genotype determination can be time-consuming.
Purpose of the Study:
- To develop and validate a rapid and accurate protocol for TPMT genotype determination.
- To assess the utility of Pyrosequencing technology for identifying known TPMT mutant alleles.
- To evaluate the efficiency of this method for large-scale genetic screening.
Main Methods:
- Developed a protocol using Pyrosequencing technology for TPMT genotype analysis.
- Amplified five key fragments of the TPMT gene (exons 4, 5, 7, 8, 10) via PCR.
- Sequenced 10 single-nucleotide polymorphisms (SNPs) associated with TPMT mutant alleles (*1S, *2, *3A-D, *4-8).
Main Results:
- The Pyrosequencing method demonstrated perfect concordance with standard DNA sequencing (BigDye terminator chemistry).
- TPMT genotyping for 10 SNPs was achieved within 30 minutes.
- The protocol was successfully applied to 96 Japanese subjects.
Conclusions:
- Pyrosequencing offers a rapid, accurate, and efficient method for TPMT genotype determination.
- This technology is highly applicable for large-scale identification of individual TPMT genotypes.
- Facilitates personalized medicine by enabling preemptive identification of patients at risk of thiopurine drug toxicity.